Eunjin Hong

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 9

Top Topics

Pseudomonas Aeruginosa

Affordable Care Act

Cystic Fibrosis

Top Venues

CPT: pharmacometrics & systems pharmacology

Clinical pharmacology and therapeutics

Pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Eunjin Hong, Paul M Beringer
Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it? CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Eunjin Hong, Marco Zampoli, Paul M Beringer
Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access. Clinical pharmacology and therapeutics (2024)
Eunjin Hong, Paul M Beringer
Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it? CPT: pharmacometrics & systems pharmacology (2024)
Eunjin Hong, Paul M Beringer
Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it? CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Eunjin Hong, Marco Zampoli, Paul M Beringer
Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access. Clinical pharmacology and therapeutics 115 (6) (2024)
Eunjin Hong, Paul M Beringer
Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it? CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Eunjin Hong, Paul M Beringer
Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it? CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Eunjin Hong, Regina Li, Alan Shi, Lisa M Almond, Joshua Wang, Amin Z Khudari, Soumar Haddad, Sarkis Sislyan, Marissa Angelich, Peter S Chung, Adupa P Rao, Paul M Beringer
Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series. Pharmacotherapy (2023)
Eunjin Hong, Regina Li, Alan Shi, Lisa M Almond, Joshua Wang, Amin Z Khudari, Soumar Haddad, Sarkis Sislyan, Marissa Angelich, Peter S Chung, Adupa P Rao, Paul M Beringer
Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: mechanistic exploration through physiologically-based pharmacokinetic modeling and a clinical case series. Pharmacotherapy (2023)